New Breast Cancer Drug Launched in UK

.

New Breast Cancer Drug Launched in UK

Patients suffering from breast cancer now have a reason to smile. A new drug produced in Japan is now all set to hit the stores in the UK. It is made by Japanese drug maker Eisai and it is a marine-based drug.

The European drug regulators passed this drug for the aid of patients suffering from the advanced stages of breast cancer. The drug is suitable for those patients who have had at least two chemotherapies but still had no effect on the cancer.

The UK has a high rate of breast cancer patients and as many as 16% deaths in the country occur due to it. As many as 30% of the women who are previously diagnosed with early stage cancer later tend to develop its advanced stages, which becomes somewhat incurable.

With the new drug in the market, there is a way for many new possibilities. The drug-maker, Eisai, is of the view that this is the first single agent treatment that has shown positive results in the patients suffering from the advanced stages of the disease.

According to Consultant Medical Oncologist Andrew Wardley Halaven, the new drug "addresses an urgent need for new treatment options for women with advanced breast cancer who have previously received multiple treatments”.


Latest News

Report Shows Large Number of Americans still Prefer Receiving Credit Card Statem
U.S. Big Banks Pass Annual Stress Test
Viacom’s Board will Remain as it is for the Time being, Judge Sets Hearing for J
Crude Stockpiles Drop in the U. S
A New Study Highlights that U. S. Expected to Spend $2.6 Trillion Less than Esti
SolarCity Shares Soar with Tesla's Bid for the Company
The Leave as well as Remain Camps Gathers Pace in Brexit
Oil’s Advance Halts as Market Awaits U.S Stock Pile Data and Brexit Poll
Martin Winterkorn and a Current VW Board Member Under Investigation by Prosecuto
Survey Shows Some Workplace Benefits are Fading with Time
Kimco Realty Corporation Shares Climbed 0.21 Percent Last Week
Sluggish Growth and Inflation is Taking More Time Than Expected Affecting Fed’s